Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatme...
Triethylenetetramine is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
University Hospitals of Leicester NHS Foundation Trust, Leicester, United Kingdom
Liverpool Heart and Chester Hospital NHS Foundation Trust, Liverpool, United Kingdom
Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Michigan, Ann Arbor, Michigan, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.